Kami Maddocks, Md
Clinical trials sponsored by Kami Maddocks, Md, explained in plain language.
-
New combo therapy shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-stage trial tests a new three-drug combination (ibrutinib, rituximab, and bendamustine) in adults with certain types of non-Hodgkin lymphoma that have come back after prior treatment. The main goal is to find the safest dose of ibrutinib when given with the other two d…
Phase: PHASE1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug ibrutinib shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis Phase 2 trial tests the drug ibrutinib in 154 people with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or B-cell prolymphocytic leukemia (B-PLL). Participants take ibrutinib pills daily for 28-day cycles. The main goal is to se…
Phase: PHASE2 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC